New drug combo before transplant aims to beat rare lymphoma

NCT ID NCT07276737

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three chemotherapy drugs (thiotepa, cyclophosphamide, and busulfan) given before a stem cell transplant for people with NK/T-cell lymphoma. The goal is to see if this approach helps keep the cancer from coming back. About 37 adults aged 18-70 who have achieved remission will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive NK-cell leukemia Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••